Paramasivam SS, et al. - In this prospective, randomized controlled, open-label trial, experts aspired to explore whether therapeutic, retrospective continuous glucose monitoring (CGM) improves HbA_1c with less hypoglycaemia in women with insulin-treated gestational diabetes mellitus (GDM). Fifty women with insulin-treated GDM randomized to either retrospective CGM (6-day sensor) at 28, 32 and 36 weeks’ gestation or usual antenatal care without CGM were evaluated. The findings from the present study suggested that CGM use could be useful in insulin-treated GDM because it improves HbA_1c compared with usual antenatal care without increasing severe hypoglycaemia.